Breaking News

Catalent, CiRA In Regenerative Therapy Pact

To manufacture mAb using GPEx technology for a clinical research project

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions has entered an agreement with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to advance one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans. Catalent will manufacture an anti-CORIN monoclonal antibody using its GPExcell line expression technology for a planned clinical research project to develop an iPS cell-based transplant therapy for Parkinson’s disease at CiRA, which is di...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters